All about health

Sienna Senior Living Inc. ("Sienna" or the "Company") today announced its financial results for the three months ended March 31, 2024. The Consolidated Financial Statements and accompanying Management's Discussion and Analysis ("MD&A") are available...

Intensity Therapeutics, Inc. ("Intensity" or "the Company") , a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer...

Kezar Life Sciences, Inc. , a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today reported financial results for the first quarter ended March 31, 2024...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m....

Alpine Immune Sciences, Inc. , a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the first quarter ended March 31, 2024. "In the first quarter of...

Sangamo Therapeutics, Inc. , a genomic medicines company, today reported business highlights and first quarter 2024 financial results. "Sangamo continues to progress its neurology-focused genomic medicine pipeline as most recently showcased at the...

Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial...

Arrowhead Pharmaceuticals, Inc. today announced financial results for its fiscal 2024 second quarter ended March 31, 2024. The Company is hosting a conference call today, May 9, 2024, at 4:30 p.m. ET to discuss the results. Christopher Anzalone,...

Equillium Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the first quarter 2024...

Arcellx, Inc. , a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first...

Insulet Corporation (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2024. First Quarter Financial...

Mind Medicine (MindMed) Inc. (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will participate...

Quantum-Si Incorporated ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Companytm, today announced financial results for the first quarter ended March 31, 2024. Press Release Highlights Reported revenue of $457,000 in the first...

Xenon Pharmaceuticals...

SenesTech, Inc. , the leader in fertility control to manage animal pest populations and the only manufacturer of commercially available, EPA-registered Rat Birth Control® products today announced financial results for the first quarter of 2024....

PacBio today announced financial results for the quarter ended March 31, 2024. First quarter results: Revenue of $38.8 million...

Cash, cash equivalents, marketable securities and restricted cash totaled approximately $287.6 million on March 31, 2024, which excludes the net proceeds of approximately $247.8 million from Biohaven's public offering completed on April 22,...

Tyra Biosciences, Inc. , a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

Initiation of global Phase 3 HARBORtm trial for del-desiran (AOC 1001) in DM1 on track for this quarter Avidity to report FSHD data from FORTITUDEtm trial this quarter and DMD data from EXPLORE44tm trial in 2H24 Presented positive long-term...

Regulus Therapeutics Inc. , a...

BioLife Solutions, Inc. ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene...

SPY001, an anti-?4?7 antibody engineered for infrequent, subcutaneous dosing successfully completed a 28-day GLP toxicity study and remains on track to begin first-in-human studies in the second quarter of 2024, with interim proof-of-concept data...

Oncolytics Biotech® Inc....

Ginkgo Bioworks Holdings, Inc. , which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2024....

Marpai, Inc. ("Marpai" or the "Company") , an independent national Third-Party Administration (TPA) company transforming the $22 billion TPA market supporting self-funded employer health plans with affordable, intelligent, healthcare, today announced...

Innocan Pharma Corporation ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful pre-clinical treatment with a liposomal-CBD injection in a female donkey. Innocan's...

Co-Diagnostics, Inc. ("Co-Dx," or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2024....

Amgen will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m. PT on Tuesday, May 14, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president...

ClearDATA®, healthcare's only comprehensive provider of cloud, compliance, and security services and software, today announced it has achieved Amazon Web Services (AWS) Level 1 Managed Security Service Provider (MSSP) Competency status, solidifying...